The company said that it identified and developed multiple synthetic processes to produce stannous protoporphyrin (SnPP), the active pharmaceutical ingredient in Renibus' RBT-9 investigational drug for treatment of COVID-19. RBT-9 has been granted a fast-track designation by the U.S. Food and Drug Administration and has shown both antiviral and immune-modulating activities in preclinical studies.

Frontier said it developed a scalable process to enable RBT-9 to be produced under commercial good manufacturing practices protocols for use in human clinical trials, according to the company. Renibus will be performing a phase II clinical trial for RBT-9 in treating COVID-19 patients who are at high risk of deteriorating health due to age or comorbid conditions such as kidney or cardiovascular disease.

Childhood vaccines may help protect against COVID-19 mortality
Could live vaccines for viruses such as measles, mumps, and rubella (MMR) also provide protection against COVID-19? That intriguing prospect is the subject...

Therapeutic Solutions to use immunotherapy for COVID-19
Therapeutic Solutions plans to develop its clinical stage cancer immunotherapy treatment StemVacs for treatment of COVID-19 patients.

Ampio begins COVID-19 phase I clinical trial for immunotherapy
Ampio Pharmaceuticals will begin a phase I clinical trial to evaluate its Ampion drug candidate for treatment of COVID-19 patients who are on supplemental...

Codagenix synthesizes live-attenuated COVID-19 vaccine
Codagenix has successfully synthesized a live-attenuated vaccine candidate for COVID-19 called CDX-005.

Yumab spinoff Corat to develop COVID-19 drug
Yumab has announced that the first financing round of its spinoff Corat Therapeutics will be used to advance the development of COVID-19 antibody drug...